Thyroid, Adrenal & Endocrine Disorders Conditions (123)
Hypothyroidism, Hashimoto thyroiditis, Graves disease, parathyroid, adrenal, and pituitary disorders.
40 Master Condition Specialty Hubs
Show All 40 Hubs ×Thyroid, Adrenal & Endocrine Disorders Guides (123)
Clear All Filters ×ACTH syndrome - ectopic
Physicians managing ACTH syndrome - ectopic (also termed Disorder or Syndrome) (E24.3; Thyroid, Adrenal & Endocrine Disorders) utilize high-resolution endocrine ultrasonography [ACTH syndrome - ectopic E24.3] and objective Morning Serum Cortisol in ACTH syndrome - ectopic (E24.3: (8 AM)) targets (10 – 18 mcg/dL (E24.3)) to prevent progression and functional morbidity.
Acromegaly
Acromegaly is an ICD-10-CM indexed diagnosis (E22.0) within Thyroid, Adrenal & Endocrine Disorders. Clinical evaluation centers on morning pituitary-target hormone in Acromegaly (E22.0: axis assays) alongside serial Thyroid-Stimulating Hormone (TSH) [Acromegaly E22.0] tracking (0.8 – 2.5 mIU/L (E22.0)) to guide individualized care.
Acromegaly and pituitary gigantism
Cataloged under federal diagnostic code E22.0 in Thyroid & Endocrine, Acromegaly and pituitary gigantism requires autoimmune antibody titers [Acromegaly and pituitary gigantism E22.0] so specialists can calibrate treatment intensity against Free Thyroxine (Free in Acromegaly and pituitary gigantism (E22.0: T4) & Free) benchmarks.
Acute thyroiditis
Acute thyroiditis—coded clinically as E06.0 across Thyroid & Endocrine guidelines—combines electrolyte-mineral balance monitoring [Acute thyroiditis E06.0] with structured follow-up of Thyroid-Stimulating Hormone (TSH) [Acute thyroiditis E06.0] (0.8 – 2.5 mIU/L (E06.0)).
Addison Disease
Your adrenal glands are just above your kidneys. The outside layer of these glands makes hormones that help your body respond to stress and regulate your blood pressure and water and salt balance. Addison disease happens if the adrenal glands don't make enough of these hormones. A problem with your immune system usually causes Addison disease. The immune system mistakenly attacks your own tissues, damaging your adrenal glands. Other causes include infections and cancer. Symptoms include: Weight loss Muscle weakness Fatigue that gets worse over time Low blood pressure Patchy or dark skin Lab tests can confirm that you have Addison disease.
Addisonian crisis
Under Thyroid, Adrenal & Endocrine Disorders diagnostic criteria (E27.2), workup for Addisonian crisis integrates dynamic endocrine stimulation/suppression in Addisonian crisis (E27.2: testing) with evidence-graded therapy tailored to Morning Serum Cortisol in Addisonian crisis (E27.2: (8 AM)) response.
Adrenal Gland Disorders
What are adrenal glands? Your adrenal glands are two small organs that sit on top of each kidney. The adrenal glands make different types of hormones you need to stay alive and healthy. Hormones are chemicals that travel in your bloodstream and control how different parts of your body work. The adrenal glands make the hormones cortisol, aldosterone, adrenaline, and noradrenaline. They also make hormones that your body uses to make sex hormones (estrogen and testosterone).
Adrenal insufficiency
Designated in federal medical registries as E27.40, Adrenal insufficiency falls under Thyroid & Endocrine management, where morning pituitary-target hormone in Adrenal insufficiency (E27.40: axis assays) establishes baseline severity and rules out diagnostic mimics.
Adrenogenital syndrome
Recognized across U.S. clinical coding as E25.9 (Thyroid & Endocrine), Adrenogenital syndrome (also termed Disorder or Syndrome) is evaluated via autoimmune antibody titers [Adrenogenital syndrome E25.9] to align day-to-day symptom relief with long-term physiological stability.
Adrenomedullary hyperfunction
Designated in federal medical registries as E27.5, Adrenomedullary hyperfunction falls under Thyroid & Endocrine management, where electrolyte-mineral balance monitoring [Adrenomedullary hyperfunction E27.5] establishes baseline severity and rules out diagnostic mimics.
Alcohol-induced pseudo-Cushing's syndrome
Alcohol-induced pseudo-Cushing's syndrome—coded clinically as E24.4 across Thyroid & Endocrine guidelines—combines electrolyte-mineral balance monitoring [Alcohol-induced pseudo-Cushing's syndrome E24.4] with structured follow-up of Morning Serum Cortisol in Alcohol-induced pseudo-Cushing's syndrome (E24.4: (8 AM)) (10 – 18 mcg/dL (E24.4)).
Alkaptonuria
Alkaptonuria—coded clinically as E70.29 across Thyroid & Endocrine guidelines—combines dynamic endocrine stimulation/suppression in Alkaptonuria (E70.29: testing) with structured follow-up of Morning Serum Cortisol in Alkaptonuria (E70.29: (8 AM)) (10 – 18 mcg/dL (E70.29)).
Atrophy of thyroid (acquired)
Physicians managing Atrophy of thyroid (acquired) (E03.4; Thyroid, Adrenal & Endocrine Disorders) utilize electrolyte-mineral balance monitoring [Atrophy of thyroid (acquired) E03.4] and objective Thyroid-Stimulating Hormone (TSH) [Atrophy of thyroid (acquired) E03.4] targets (0.8 – 2.5 mIU/L (E03.4)) to prevent progression and functional morbidity.
Bartter syndrome
Designated in federal medical registries as E26.81, Bartter syndrome (also termed Disorder or Syndrome) falls under Thyroid & Endocrine management, where high-resolution endocrine ultrasonography [Bartter syndrome E26.81] establishes baseline severity and rules out diagnostic mimics.
Carcinoid syndrome
Carcinoid syndrome (also termed Disorder or Syndrome) is an ICD-10-CM indexed diagnosis (E34.00) within Thyroid, Adrenal & Endocrine Disorders. Clinical evaluation centers on electrolyte-mineral balance monitoring [Carcinoid syndrome E34.00] alongside serial Thyroid-Stimulating Hormone (TSH) [Carcinoid syndrome E34.00] tracking (0.8 – 2.5 mIU/L (E34.00)) to guide individualized care.
Chronic thyroiditis with transient thyrotoxicosis
Clinical triage of Chronic thyroiditis with transient thyrotoxicosis (E06.2) in Thyroid & Endocrine relies on morning pituitary-target hormone in Chronic thyroiditis with transient thyrotoxicosis (E06.2: axis assays), guiding step-wise therapeutic adjustments toward Morning Serum Cortisol in Chronic thyroiditis with transient thyrotoxicosis (E06.2: (8 AM)) (10 – 18 mcg/dL (E06.2)).
Congenital adrenal hyperplasia (CAH)
Recognized across U.S. clinical coding as E25.0 (Thyroid & Endocrine), Congenital adrenal hyperplasia (CAH) (also termed Congenital or Born with) is evaluated via high-resolution endocrine ultrasonography [Congenital adrenal hyperplasia (CAH) E25.0] to align day-to-day symptom relief with long-term physiological stability.
Congenital hypothyroidism with diffuse goiter
Physicians managing Congenital hypothyroidism with diffuse goiter (E03.0; Thyroid, Adrenal & Endocrine Disorders) utilize autoimmune antibody titers [Congenital hypothyroidism with diffuse goiter E03.0] and objective Thyroid-Stimulating Hormone (TSH) [Congenital hypothyroidism with diffuse goiter E03.0] targets (0.8 – 2.5 mIU/L (E03.0)) to prevent progression and functional morbidity.
Congenital hypothyroidism without goiter
Congenital hypothyroidism without goiter—coded clinically as E03.1 across Thyroid & Endocrine guidelines—combines morning pituitary-target hormone in Congenital hypothyroidism without goiter (E03.1: axis assays) with structured follow-up of Thyroid-Stimulating Hormone (TSH) [Congenital hypothyroidism without goiter E03.1] (0.8 – 2.5 mIU/L (E03.1)).
Congenital iodine-deficiency syndrome
Congenital iodine-deficiency syndrome is an ICD-10-CM indexed diagnosis (E00.9) within Thyroid, Adrenal & Endocrine Disorders. Clinical evaluation centers on morning pituitary-target hormone in Congenital iodine-deficiency syndrome (E00.9: axis assays) alongside serial Thyroid-Stimulating Hormone (TSH) [Congenital iodine-deficiency syndrome E00.9] tracking (0.8 – 2.5 mIU/L (E00.9)) to guide individualized care.
Congenital iodine-deficiency syndrome, mixed type
Designated in federal medical registries as E00.2, Congenital iodine-deficiency syndrome, mixed type falls under Thyroid & Endocrine management, where autoimmune antibody titers [Congenital iodine-deficiency syndrome, mixed type E00.2] establishes baseline severity and rules out diagnostic mimics.
Congenital iodine-deficiency syndrome, myxedematous type
Under Thyroid, Adrenal & Endocrine Disorders diagnostic criteria (E00.1), workup for Congenital iodine-deficiency syndrome, myxedematous type integrates high-resolution endocrine ultrasonography [Congenital iodine-deficiency syndrome, myxedematous type E00.1] with evidence-graded therapy tailored to Thyroid-Stimulating Hormone (TSH) [Congenital iodine-deficiency syndrome, myxedematous type E00.1] response.
Congenital iodine-deficiency syndrome, neurological type
Congenital iodine-deficiency syndrome, neurological type—coded clinically as E00.0 across Thyroid & Endocrine guidelines—combines morning pituitary-target hormone in Congenital iodine-deficiency syndrome, neurological type (E00.0: axis assays) with structured follow-up of Morning Serum Cortisol in Congenital iodine-deficiency syndrome, neurological type (E00.0: (8 AM)) (10 – 18 mcg/dL (E00.0)).
Copper deficiency
Cataloged under federal diagnostic code E61.0 in Thyroid & Endocrine, Copper deficiency (also termed Copper or Cu+2) requires electrolyte-mineral balance monitoring [Copper deficiency E61.0] so specialists can calibrate treatment intensity against Free Thyroxine (Free in Copper deficiency (E61.0: T4) & Free) benchmarks.
Cushing Syndrome
What is Cushing syndrome? Cushing syndrome is a hormonal disorder. It happens when your body has too much of a hormone called cortisol over a long period of time. Hormones are chemical messengers in your bloodstream that control the actions of certain cells or organs. Cortisol is made by your adrenal glands, two small glands that sit above your kidneys.
Cushing's disease
Designated in federal medical registries as E24.0, Cushing's disease falls under Thyroid & Endocrine management, where high-resolution endocrine ultrasonography [Cushing's disease E24.0] establishes baseline severity and rules out diagnostic mimics.
Cystinuria
Designated in federal medical registries as E72.01, Cystinuria falls under Thyroid & Endocrine management, where autoimmune antibody titers [Cystinuria E72.01] establishes baseline severity and rules out diagnostic mimics.
Disaccharidase deficiency
Under Thyroid, Adrenal & Endocrine Disorders diagnostic criteria (E73.9), workup for Disaccharidase deficiency (also termed Decreased or Diminished) integrates high-resolution endocrine ultrasonography [Disaccharidase deficiency E73.9] with evidence-graded therapy tailored to Morning Serum Cortisol in Disaccharidase deficiency (E73.9: (8 AM)) response.
Disorder of adrenal gland
Designated in federal medical registries as E27.9, Disorder of adrenal gland falls under Thyroid & Endocrine management, where dynamic endocrine stimulation/suppression in Disorder of adrenal gland (E27.9: testing) establishes baseline severity and rules out diagnostic mimics.
Disorder of parathyroid gland
For patients presenting with Disorder of parathyroid gland (ICD-10-CM E21.5), Thyroid, Adrenal & Endocrine Disorders protocols prioritize autoimmune antibody titers [Disorder of parathyroid gland E21.5] paired with baseline and interval Morning Serum Cortisol in Disorder of parathyroid gland (E21.5: (8 AM)) assessment.
Disorder of thyroid
Within Thyroid, Adrenal & Endocrine Disorders practice, Disorder of thyroid (ICD-10 E07.9) is stratified through morning pituitary-target hormone in Disorder of thyroid (E07.9: axis assays), pairing targeted symptom control with longitudinal Free Thyroxine (Free in Disorder of thyroid (E07.9: T4) & Free) surveillance.
Drug-induced Cushing's syndrome
Recognized across U.S. clinical coding as E24.2 (Thyroid & Endocrine), Drug-induced Cushing's syndrome is evaluated via electrolyte-mineral balance monitoring [Drug-induced Cushing's syndrome E24.2] to align day-to-day symptom relief with long-term physiological stability.
Drug-induced adrenocortical insufficiency
Within Thyroid, Adrenal & Endocrine Disorders practice, Drug-induced adrenocortical insufficiency (ICD-10 E27.3) is stratified through dynamic endocrine stimulation/suppression in Drug-induced adrenocortical insufficiency (E27.3: testing), pairing targeted symptom control with longitudinal Free Thyroxine (Free in Drug-induced adrenocortical insufficiency (E27.3: T4) & Free) surveillance.
Drug-induced thyroiditis
For patients presenting with Drug-induced thyroiditis (ICD-10-CM E06.4), Thyroid, Adrenal & Endocrine Disorders protocols prioritize morning pituitary-target hormone in Drug-induced thyroiditis (E06.4: axis assays) paired with baseline and interval Thyroid-Stimulating Hormone (TSH) [Drug-induced thyroiditis E06.4] assessment.
Dyshormogenetic goiter
Clinical triage of Dyshormogenetic goiter (E07.1) in Thyroid & Endocrine relies on electrolyte-mineral balance monitoring [Dyshormogenetic goiter E07.1], guiding step-wise therapeutic adjustments toward Morning Serum Cortisol in Dyshormogenetic goiter (E07.1: (8 AM)) (10 – 18 mcg/dL (E07.1)).
Empty sella syndrome
Within Thyroid, Adrenal & Endocrine Disorders practice, Empty sella syndrome (also termed Disorder or Syndrome) (ICD-10 E23.6) is stratified through electrolyte-mineral balance monitoring [Empty sella syndrome E23.6], pairing targeted symptom control with longitudinal Free Thyroxine (Free in Empty sella syndrome (E23.6: T4) & Free) surveillance.
Fanconi syndrome
Physicians managing Fanconi syndrome (also termed Disorder or Syndrome) (E72.09; Thyroid, Adrenal & Endocrine Disorders) utilize autoimmune antibody titers [Fanconi syndrome E72.09] and objective Morning Serum Cortisol in Fanconi syndrome (E72.09: (8 AM)) targets (10 – 18 mcg/dL (E72.09)) to prevent progression and functional morbidity.
Fructose intolerance
Physicians managing Fructose intolerance (E74.12; Thyroid, Adrenal & Endocrine Disorders) utilize autoimmune antibody titers [Fructose intolerance E74.12] and objective Morning Serum Cortisol in Fructose intolerance (E74.12: (8 AM)) targets (10 – 18 mcg/dL (E74.12)) to prevent progression and functional morbidity.
Galactosemia
Physicians managing Galactosemia (E74.21; Thyroid, Adrenal & Endocrine Disorders) utilize electrolyte-mineral balance monitoring [Galactosemia E74.21] and objective Morning Serum Cortisol in Galactosemia (E74.21: (8 AM)) targets (10 – 18 mcg/dL (E74.21)) to prevent progression and functional morbidity.
Gauchers disease
Recognized across U.S. clinical coding as E75.22 (Thyroid & Endocrine), Gauchers disease is evaluated via electrolyte-mineral balance monitoring [Gauchers disease E75.22] to align day-to-day symptom relief with long-term physiological stability.
Goiter - multinodular
Recognized across U.S. clinical coding as E04.2 (Thyroid & Endocrine), Goiter - multinodular (also termed Nodule or Nodular) is evaluated via dynamic endocrine stimulation/suppression in Goiter - multinodular (E04.2: testing) to align day-to-day symptom relief with long-term physiological stability.
Graves disease
Cataloged under federal diagnostic code E05.00 in Thyroid & Endocrine, Graves disease requires high-resolution endocrine ultrasonography [Graves disease E05.00] so specialists can calibrate treatment intensity against Free Thyroxine (Free in Graves disease (E05.00: T4) & Free) benchmarks.
HGPRT deficiency
Physicians managing HGPRT deficiency (also termed Decreased or Diminished) (E79.1; Thyroid, Adrenal & Endocrine Disorders) utilize morning pituitary-target hormone in HGPRT deficiency (E79.1: axis assays) and objective Morning Serum Cortisol in HGPRT deficiency (E79.1: (8 AM)) targets (10 – 18 mcg/dL (E79.1)) to prevent progression and functional morbidity.
Hartnup disease
Hartnup disease—coded clinically as E72.02 across Thyroid & Endocrine guidelines—combines high-resolution endocrine ultrasonography [Hartnup disease E72.02] with structured follow-up of Morning Serum Cortisol in Hartnup disease (E72.02: (8 AM)) (10 – 18 mcg/dL (E72.02)).
Hashimoto thyroiditis
Physicians managing Hashimoto thyroiditis (E06.3; Thyroid, Adrenal & Endocrine Disorders) utilize autoimmune antibody titers [Hashimoto thyroiditis E06.3] and objective Thyroid-Stimulating Hormone (TSH) [Hashimoto thyroiditis E06.3] targets (0.8 – 2.5 mIU/L (E06.3)) to prevent progression and functional morbidity.
Hemosiderosis
Cataloged under federal diagnostic code E83.19 in Thyroid & Endocrine, Hemosiderosis requires dynamic endocrine stimulation/suppression in Hemosiderosis (E83.19: testing) so specialists can calibrate treatment intensity against Free Thyroxine (Free in Hemosiderosis (E83.19: T4) & Free) benchmarks.
Homocystinuria
Physicians managing Homocystinuria (E72.11; Thyroid, Adrenal & Endocrine Disorders) utilize high-resolution endocrine ultrasonography [Homocystinuria E72.11] and objective Morning Serum Cortisol in Homocystinuria (E72.11: (8 AM)) targets (10 – 18 mcg/dL (E72.11)) to prevent progression and functional morbidity.
Hyperaldosteronism
Within Thyroid, Adrenal & Endocrine Disorders practice, Hyperaldosteronism (ICD-10 E26.9) is stratified through morning pituitary-target hormone in Hyperaldosteronism (E26.9: axis assays), pairing targeted symptom control with longitudinal TPO & Thyroglobulin in Hyperaldosteronism (E26.9: Antibodies) surveillance.
Hyperfunction of pituitary gland
Recognized across U.S. clinical coding as E22.9 (Thyroid & Endocrine), Hyperfunction of pituitary gland is evaluated via high-resolution endocrine ultrasonography [Hyperfunction of pituitary gland E22.9] to align day-to-day symptom relief with long-term physiological stability.
Hyperparathyroidism
Physicians managing Hyperparathyroidism (E21.3; Thyroid, Adrenal & Endocrine Disorders) utilize electrolyte-mineral balance monitoring [Hyperparathyroidism E21.3] and objective Morning Serum Cortisol in Hyperparathyroidism (E21.3: (8 AM)) targets (10 – 18 mcg/dL (E21.3)) to prevent progression and functional morbidity.
Hyperthyroidism
What is hyperthyroidism? Hyperthyroidism, or overactive thyroid, happens when your thyroid gland makes more thyroid hormones than your body needs. Your thyroid is a small, butterfly-shaped gland in the front of your neck. It makes hormones that control the way the body uses energy. These hormones affect nearly every organ in your body and control many of your body's most important functions. For example, they affect your breathing, heart rate, weight, digestion, and moods. If not treated, hyperthyroidism can cause serious problems with your heart, bones, muscles, menstrual cycle, and fertility. But there are treatments that can help.
Hypoaldosteronism
Clinical triage of Hypoaldosteronism (E27.40) in Thyroid & Endocrine relies on dynamic endocrine stimulation/suppression in Hypoaldosteronism (E27.40: testing), guiding step-wise therapeutic adjustments toward Morning Serum Cortisol in Hypoaldosteronism (E27.40: (8 AM)) (10 – 18 mcg/dL (E27.40)).
Hypoparathyroidism
Clinical triage of Hypoparathyroidism (E20.9) in Thyroid & Endocrine relies on high-resolution endocrine ultrasonography [Hypoparathyroidism E20.9], guiding step-wise therapeutic adjustments toward Thyroid-Stimulating Hormone (TSH) [Hypoparathyroidism E20.9] (0.8 – 2.5 mIU/L (E20.9)).
Hypothyroidism
What is hypothyroidism? Hypothyroidism, or underactive thyroid, happens when your thyroid gland doesn't make enough thyroid hormones to meet your body's needs. Your thyroid is a small, butterfly-shaped gland in the front of your neck. It makes hormones that control the way the body uses energy. These hormones affect nearly every organ in your body and control many of your body's most important functions. For example, they affect your breathing, heart rate, weight, digestion, and moods. Without enough thyroid hormones, many of your body's functions slow down. But there are treatments that can help. What causes hypothyroidism? Hypothyroidism has several causes.
Hypothyroidism due to medicaments and other exogenous substances
Under Thyroid, Adrenal & Endocrine Disorders diagnostic criteria (E03.2), workup for Hypothyroidism due to medicaments and other exogenous substances integrates autoimmune antibody titers [Hypothyroidism due to medicaments and other exogenous substances E03.2] with evidence-graded therapy tailored to Morning Serum Cortisol in Hypothyroidism due to medicaments and other exogenous substances (E03.2: (8 AM)) response.
Idiopathic hypoparathyroidism
Cataloged under federal diagnostic code E20.0 in Thyroid & Endocrine, Idiopathic hypoparathyroidism requires electrolyte-mineral balance monitoring [Idiopathic hypoparathyroidism E20.0] so specialists can calibrate treatment intensity against Free Thyroxine (Free in Idiopathic hypoparathyroidism (E20.0: T4) & Free) benchmarks.
Iodine-deficiency related (endemic) goiter
Iodine-deficiency related (endemic) goiter is an ICD-10-CM indexed diagnosis (E01.2) within Thyroid, Adrenal & Endocrine Disorders. Clinical evaluation centers on autoimmune antibody titers [Iodine-deficiency related (endemic) goiter E01.2] alongside serial Thyroid-Stimulating Hormone (TSH) [Iodine-deficiency related (endemic) goiter E01.2] tracking (0.8 – 2.5 mIU/L (E01.2)) to guide individualized care.
Iodine-deficiency related multinodular (endemic) goiter
Iodine-deficiency related multinodular (endemic) goiter—coded clinically as E01.1 across Thyroid & Endocrine guidelines—combines high-resolution endocrine ultrasonography [Iodine-deficiency related multinodular (endemic) goiter E01.1] with structured follow-up of Morning Serum Cortisol in Iodine-deficiency related multinodular (endemic) goiter (E01.1: (8 AM)) (10 – 18 mcg/dL (E01.1)).
Keratosis - inverted follicular
Cataloged under federal diagnostic code E50.8 in Thyroid & Endocrine, Keratosis - inverted follicular (also termed Flipped or Inverted) requires dynamic endocrine stimulation/suppression in Keratosis - inverted follicular (E50.8: testing) so specialists can calibrate treatment intensity against TPO & Thyroglobulin in Keratosis - inverted follicular (E50.8: Antibodies) benchmarks.
Magnesium - high
Magnesium - high (also termed Hypermagnesemia)—coded clinically as E83.41 across Thyroid & Endocrine guidelines—combines electrolyte-mineral balance monitoring [Magnesium - high E83.41] with structured follow-up of Thyroid-Stimulating Hormone (TSH) [Magnesium - high E83.41] (0.8 – 2.5 mIU/L (E83.41)).